Agilent Technologies Announces Business Segment Reorganization

Details

announced a reorganization of its business segments by moving the Cell Analysis Division into the Diagnostics and Genomics Group (DGG) from the Life Sciences and Applied Markets Group (LSAG). This change will strengthen growth opportunities for both segments and will be reflected in the financial statements starting with the quarter ending January 31, 2024. Selected segment information for the fiscal quarters and years ended October 31, 2021, 2022, and 2023, has been furnished to show the impact of this reorganization on the company's reportable segments.

Items reported

Exhibits (1)

About Agilent Technologies Inc.

Agilent Technologies Inc. is a global leader in the development and provision of life sciences, diagnostics, and applied chemical markets. Primarily focused on delivering superior analytical instruments, software, services, consumables, and reagents, the company plays a critical role in supporting the research needs of pharmaceutical, biotechnology, and government laboratories. Agilent's robust portfolio includes innovative solutions for genomics, proteomics, and metabolomics, aiding in critical areas such as disease research, food safety, and environmental analysis. Established in 1999 as a spin-off from Hewlett-Packard, the company leverages its heritage of technological innovation to enhance analytical capabilities for its clients. Agilent's significant contributions to health and safety applications underscore its importance in advancing scientific understanding and supporting public health initiatives worldwide.